INO trade ideas
INO What You're Thinking...INO finally broke back above the 786 fib line. Before the last bout of selling, you'll see this level was an area of support for the former penny stock. Now, thanks to some added excitement from delta news (the variant not the airline), INO shares are popping. They also jumped back above the 786 fib. Now the question is, will it rest the 618 fib like it tried to a few weeks ago?
"Inovio Pharmaceuticals Inc. (NASDAQ: INO) has steadily climbed for the better part of the last 3 months thanks to recent pipeline progress. In June, the company had expanded its partnership with Advaccine Biopharmaceuticals Suzhou to conduct a Phase 3 segment of a trial called INNOVATE. The goal is to evaluate the safety and efficacy of the company’s INO-4800 in COVID patients. The treatment was already shown to be well tolerated and immunogenic in tested age groups in a Phase 2 study.
This month Inovio announced that it and Advaccine received a regulatory allowance for 2 heterologous prime-boost clinical trials in China using INO-4800. “VID-19. If approved, we believe INO-4800 will be well-positioned to serve the vaccine needs of the global community as both a primary and a booster vaccine due to its tolerability, balanced cross-reactive immune responses, and strong thermostability profile that does not require cold or ultra-cold-chain transport,” said Dr. J. Joseph Kim, President, and CEO of INOVIO."
Quote Source & Read more on INO: Former Penny Stocks To Watch After Merck’s ( MRK ) Latest FDA Win
Inovio D1In May, Inovio said it would begin the study of INO-4800 in summer this year, after the vaccine candidate was found to be safe as well as well-tolerated and produced an immune response against the new coronavirus in a mid-stage clinical trial. read more
The company started developing INO-4800 last year, but fell behind rivals after the U.S. Food and Drug Administration (FDA) put a part of the U.S. study on hold for more information on the vaccine delivery device.
The FDA's decision was followed by the U.S. government pulling funding for the late-stage study, citing the fast-moving environment of vaccine development.
The global trial will initially focus on Latin America, Asia Pacific and regions in Africa, the company said.
"We were initially focusing on Latin America and Asia Pacific, but looking at the rapidly changing vaccination rates and the virus epidemiology, we are including regions in Africa," a company executive said during a post-earnings call on Monday.
Inovio, which has no approved drug on the market, has so far received about $85 million in combined funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation and the U.S. Department of Defense for the advancement and manufacture of INO-4800.
Earlier this year, Inovio expanded a partnership with China's Advaccine Biopharmaceuticals to conduct the late-stage trial. Under the expanded deal, the companies expect to equally share its total cost.
Inovio D1In May, Inovio said it would begin the study of INO-4800 in summer this year, after the vaccine candidate was found to be safe as well as well-tolerated and produced an immune response against the new coronavirus in a mid-stage clinical trial. read more
The company started developing INO-4800 last year, but fell behind rivals after the U.S. Food and Drug Administration (FDA) put a part of the U.S. study on hold for more information on the vaccine delivery device.
The FDA's decision was followed by the U.S. government pulling funding for the late-stage study, citing the fast-moving environment of vaccine development.
The global trial will initially focus on Latin America, Asia Pacific and regions in Africa, the company said.
"We were initially focusing on Latin America and Asia Pacific, but looking at the rapidly changing vaccination rates and the virus epidemiology, we are including regions in Africa," a company executive said during a post-earnings call on Monday.
Inovio, which has no approved drug on the market, has so far received about $85 million in combined funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation and the U.S. Department of Defense for the advancement and manufacture of INO-4800.
Earlier this year, Inovio expanded a partnership with China's Advaccine Biopharmaceuticals to conduct the late-stage trial. Under the expanded deal, the companies expect to equally share its total cost.
Inovio Pharma looks like ready to flip bullishEarnings calls are always kinda of a gamble, but on grand/macro scale $INO looks ready to turn bullish (short to mid term)...
Maxx Momentum is signaling a squeeze on D1 and W charts (a squeeze can be in either direction), and KST just signaled a buy on both time frames as well. RSI on daily is a bit extended, while on weekly it sits comfy at the median line. Just looking at some pitchforks as well, the big channel from May low to June High and August Low is holding perfectly and should jump to the upwards.
On weekly we are riding 200 EMA and actively flirting with 21 and 25 EMA, trying to flip it over and turning to daily, we can see...
That we are just approaching 200 EMA, where we will try to re-claim it as support, with some help of previously mentioned lover EMAs.
While I am already long with entry at 8.80, I am looking to add to that long when and if we flip it over with 200 EMA as showed on the chart (flexible entry point around 10.50). I am using 2x lever on both.
Obviously if we get the flip, I am adjusting my lower entry SL to higher entries SL, so I cover my possible losses of higher entry with gains from lower entry, which makes this trade extremely low risk. But I do think we have a good chance of visiting 14USD golden zone per share, where I will be closely monitoring live price action, to see if taking partial profits is viable there. If we aggressively pierce through that level, that would be best possible scenario, but I would not be supprised with a V topping formation over there, in that case, RSI on 12h chart will help me address the question of how much partials should I take there and the size of runners towards 16 USD. This risk to rewards ratio is for the taking.
Have a great day everyone.
INOVIO- INTRADAY INO - Buyers volume is there on the break out of today's chart, it is expected to go up from the current levels only if sustains above 9.75
Maintain stop loss around 9.1
Potential upside target 10.25
If sustains below 9.75 go short with the stop loss around 9.85 with the target of 9.35.
Hit the like button to get more such signals
INO Technical Analysis 🧙Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
INO: reversal of the positive courseINO’s short-term trend chart is presented. ___
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
